| Gene |
[TARDBP](/genes/tardbp) |
| UniProt |
Q13148 |
| PDB |
2N4P, 5E1O, 6N3T |
| Mol. Weight |
44.7 kDa (full-length), 43 kDa (cleaved) |
| Localization |
Nucleus, cytoplasm |
| Family |
Heterogeneous nuclear ribonucleoprotein (hnRNP) family |
| Diseases |
[Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/ftd), [Alzheimer's Disease](/diseases/alzheimers) |
TAR DNA-Binding Protein 43 (TDP-43) is a 414-amino acid nuclear protein encoded by the TARDBP gene on chromosome 1p36.22 that plays a critical role in RNA metabolism and has emerged as a central player in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 is the major constituent of cytoplasmic inclusions found in approximately 95% of ALS cases and 50% of FTD cases, making it one of the most important pathological proteins in neurodegenerative disease.
The discovery of TDP-43 as the pathological protein in ALS and FTD in 2006 by Neumann et al. revolutionized our understanding of these diseases and revealed unexpected links between apparently distinct neurodegenerative conditions. This 43 kDa protein, initially characterized as a transcriptional repressor binding to the TAR DNA element of HIV-1, has since been shown to be a master regulator of RNA metabolism with roles in splicing, stability, transport, and translation.
TDP-43 contains several distinct structural domains, each with specific functional properties:
¶ N-Terminal Domain (residues 1-102)
The N-terminal domain contains:
- Nuclear Localization Signal (NLS): Residues 82-98, a basic region mediating importin-α/β binding
- Dimerization domain: Enables TDP-43 to form homodimers and higher-order oligomers
- Nuclear export signal (NES): Recently identified in this region
The NLS is crucial for nuclear import, and mutations or post-translational modifications affecting this region contribute to disease pathogenesis.
RRM1 is the primary RNA/DNA-binding domain:
- Recognition motif: RRM1 has high affinity for UG-rich sequences (TAR DNA, UG repeats)
- Structure: Classical RRM fold with RNP1 and RNP2 consensus sequences
- Binding specificity: Single-stranded DNA and RNA, with preference for pyrimidine-rich sequences
- Function: Mediates both transcriptional repression and RNA splicing regulation
RRM2 works in concert with RRM1:
- Auxiliary RNA binding: Enhances specificity and affinity for target RNAs
- Splicing regulation: Critical for exon skipping events (e.g., CFTR exon 9, SMN2 exon 7)
- Structural role: Stabilizes RRM1 binding through inter-domain interactions
¶ Glycine-Rich Domain (residues 274-306)
The glycine-rich region mediates protein-protein interactions:
- HnRNP interactions: Binds to other hnRNP proteins (A1, A2/B1, C)
- Splicing factors: Interacts with spliceosomal components
- ** transcriptional co-activators**: Associates with p300/CBP and other regulators
¶ C-Terminal Prion Domain (residues 307-414)
The C-terminal region is intrinsically disordered and aggregation-prone:
- Q/N-rich sequence: Glutamine/asparagine-rich prion-like domain
- Aggregation nucleation: Site of pathological aggregation in disease
- Most disease mutations: >90% of ALS-associated TARDBP mutations occur here
- Stress granule recruitment: Mediates liquid-liquid phase separation
TDP-43 undergoes numerous PTMs that regulate its function and aggregation:
| Modification |
Site |
Effect |
| Phosphorylation |
Ser379, Ser409, Ser410, Ser383/Ser409 |
Marker of pathological aggregation |
| Ubiquitination |
Multiple Lys residues |
Degradation signal, found in inclusions |
| SUMOylation |
Lys |
May protect from degradation |
| Acetylation |
Multiple Lys |
Reduces RNA binding |
| Cleavage |
Asp219, Asp89 |
Generates aggregation-prone fragments |
| Methylation |
Arg |
Alters protein interactions |
C-terminal truncation of TDP-43 is a hallmark of disease:
- C-terminal fragments (CTFs): 25-35 kDa fragments found in inclusions
- Generation by caspases: Caspase-3 cleavage at Asp219
- Aggregation-prone: Truncated forms seed full-length protein aggregation
- Toxicity: CTFs are more toxic than full-length protein
TDP-43 is a multifunctional RNA-binding protein involved in:
TDP-43 regulates the splicing of hundreds of neuronal transcripts:
- SMN2 exon 7: Critical modifier of spinal muscular atrophy
- CFTR exon 9: Regulator of chloride channel splicing
- NLGN1/3: Synaptic adhesion proteins
- MAPT exon 10: Tau isoform regulation
- UNC13A: Synaptic vesicle release
¶ RNA Stability and Transport
- 3' UTR binding: Regulates mRNA stability
- RNA transport granules: Facilitates dendritic mRNA localization
- Translation regulation: Controls translation of target mRNAs
- Long non-coding RNAs: Processing of MALAT1, NEAT1
- TAR DNA binding: Originally characterized as HIV-1 TAR repressor
- Chromatin remodeling: Associates with epigenetic regulators
- Gene expression: Modulates transcription of neuronal genes
TDP-43 dynamically shuttles between nucleus and cytoplasm:
- Import: Importin-α/β mediated, requires NLS
- Export: Exportin-1 (CRM1) dependent, requires NES
- Stress conditions: Increased cytoplasmic localization
- Cellular stress response: Stress granule formation
Under cellular stress, TDP-43 localizes to stress granules:
- Formation: Liquid-liquid phase separation under stress
- Composition: G3BP1, TIA-1, PABP1, other RBPs
- Function: Temporarily sequester mRNAs for survival
- Disease link: Prolonged stress → irreversible aggregation
Despite its name, TDP-43 has multiple DNA-binding functions:
- Genomic integrity: Binds to DNA damage response elements
- Telomere regulation: Associates with telomeric DNA
- Retrotransposon control: May regulate LINE-1 elements
¶ Pathogenesis in ALS and FTD
The hallmark of ALS/FTD is cytoplasmic TDP-43 inclusion formation:
flowchart TD
A["Normal TDP-43<br/>Nuclear → BStress Response"]
B --> C["Stress Granules"]
C -->|"Prolonged stress"| D["Misfolding"]
D --> E["Aggregation"]
E --> F["Cytoplasmic Inclusions"]
F --> G["Nuclear Depletion"]
G --> H["RNA Dysregulation"]
H --> I["Neuronal Dysfunction"]
I --> J["Neurodegeneration"]
C -->|"Reversible"| A
E -->|"Propagation"| K["Neighbor Cells"]
Cytoplasmic aggregation leads to nuclear depletion:
- RNA splicing disruption: Loss of nuclear TDP-43 causes missplicing
- Target transcript changes: >100 transcripts dysregulated
- Neuronal vulnerability: Specific exon patterns affected
- Cell death: Correlates with neurodegeneration
Cytoplasmic aggregates cause toxicity through:
- RNA sequestration: Traps other RBPs in aggregates
- Stress granule persistence: Prevents stress recovery
- Proteostasis disruption: Overwhelms degradation systems
- Mitochondrial dysfunction: Indirect effects on energy metabolism
Over 50 mutations in TARDBP cause ALS/FTD:
| Mutation |
Location |
Effect |
| A315T |
C-terminal |
Most common, early onset |
| M337V |
C-terminal |
Highly penetrant |
| G348C |
C-terminal |
Rapid progression |
| N390D |
C-terminal |
Variable phenotype |
| Q331K |
C-terminal |
Motor neuron predominant |
| G294V |
C-terminal |
FTD predominant |
| K263E |
RRM1 |
Early onset |
- RNA splicing disruption: Aberrant splicing of critical neuronal transcripts
- Mitochondrial dysfunction: Energy metabolism impairment
- Oxidative stress: Increased ROS production
- Autophagy impairment: Defective protein clearance
- Nucleocytoplasmic transport disruption: Nuclear pore dysfunction
- Stress granule dysregulation: Persistent granules
Emerging evidence suggests TDP-43 forms distinct strains:
- Conformational variants: Different aggregate structures
- Cell-to-cell transmission: Prion-like propagation
- Phenotypic variability: Strain differences may explain disease variability
- Strain detection: RT-QuIC and other amplification assays
While not the primary pathology in AD, TDP-43 is commonly observed:
- Prevalence: Found in up to 50% of AD cases
- Distribution: Limbic regions, amygdala
- Impact: May accelerate cognitive decline
- Co-pathology: Often with tau and amyloid
Limbic-predominant Age-related TDP-43 Encephalopathy:
- Clinical syndrome: Late-onset dementia mimicking AD
- Pathology: TDP-43 in limbic regions without ALS/FTD
- Prevalence: Common in oldest-old
- Biomarkers: Under development
| Model |
Mutation |
Phenotype |
Notes |
| TDP-43Q331K |
Human Q331K |
Age-dependent motor dysfunction |
Knockin |
| TDP-43M337V |
Human M337V |
Motor neuron degeneration |
Transgenic |
| TDP-43ΔNLS |
NLS deletion |
Cytoplasmic aggregation |
Inducible |
| TDP-43WT |
Wild-type |
Moderate pathology |
Overexpression |
- Nuclear loss is sufficient: NLS mutation causes neurodegeneration
- Cell non-autonomous: Glia contribute to pathology
- Propagation: Injected seeds cause pathology
- Therapeutic targets: Support multiple intervention strategies
- Mosaicin: Natural compound reducing aggregation
- Anle138b: Oligomer modulator, shows efficacy in mice
- YKL-40: Chitinase-like protein, biomarker and target
- Doxycycline: FDA-approved, shows promise in trials
- Autophagy enhancers: Rapamycin, trehalose
- Antioxidants: CoQ10, edaravone
- Anti-inflammatory: Microglial modulators
ASO therapy represents a promising approach:
- Mechanism: Reduce TDP-43 expression
- Delivery: Intrathecal administration
- Challenges: Need to maintain nuclear function
- Status: Pre-clinical development
- Wild-type TDP-43 delivery: Restore nuclear function
- Anti-aggregation proteins: Molecular chaperones
- RNA targeting: CRISPR-based approaches
- Cell replacement: Stem cell therapies
- Anti-TDP-43 antibodies: Active/passive immunization
- Antibody engineering: Enhanced brain penetration
- Vaccination strategies: Prevention in at-risk populations
| Biomarker |
Change |
Utility |
| Total TDP-43 |
Increased |
Disease progression |
| Phospho-TDP-43 |
Increased |
Specific to pathology |
| TDP-43 fragments |
Increased |
Disease severity |
- Neurofilament light chain (NfL): Disease progression marker
- Phospho-TDP-43: Emerging blood test
- Cell-free DNA: Potential for detection
- TDP-43 PET ligands: Under development
- Structural MRI: Pattern of atrophy
- PET markers: Metabolic changes
- Autosomal dominant: Most mutations
- Variable penetrance: Age-dependent
- Phenotypic spectrum: ALS to FTD
- Population genetics: Founder effects in some groups
- Common variants: GWAS hits near TARDBP
- Epigenetic changes: Altered methylation in disease
- Gene expression: Dysregulation in affected tissues
- C9orf72: Most common genetic cause
- FUS: Another RNA-binding protein
- GRN: Progranulin, lysosomal function
- TBK1: Autophagy/innate immunity
- Neuronal cytoplasmic inclusions (NCIs): Most common
- Neuronal nuclear inclusions (NNIs): Less common
- Glial inclusions: In some cases
- Pristine inclusions: Rare, poorly characterized
ALS:
- Motor cortex
- Spinal cord motor neurons
- Bulbar nuclei
- Frontal cortex (some cases)
FTD:
- Frontal and temporal cortex
- Basal ganglia
- Limbic system
- Motor cortex (overlap)
- ALS staging: Braak-like progression
- FTD staging:新 cortical involvement
- LATE staging: Limbic predominance
| Protein |
Function |
Disease Relevance |
| hnRNP A1 |
Splicing |
Co-aggregation |
| hnRNP A2/B1 |
RNA transport |
Co-aggregation |
| FUS |
RNA metabolism |
ALS/FTD gene |
| TAF15 |
Transcription |
ALS/FTD gene |
| SMN complex |
Splicing |
SMA modifier |
| Importins |
Nuclear import |
Transport deficit |
- Critical transcripts: >30% of brain transcripts
- Functional categories: Synaptic, mitochondrial, survival
- Dysregulation patterns: Disease-specific signatures
- Strain biology: Understanding TDP-43 variants
- Propagation mechanisms: Cell-to-cell spread
- Systems biology: Network-level understanding
- Biomarker development: Early detection
- Combination therapies: Multi-target approaches
- Genetic stratification: Mutation-specific therapies
- Biomarker-guided: Patient selection
- Stage-specific: Early vs late intervention
- Personalized: Individualized treatment plans
¶ Cellular and Animal Models
- Motor neuron lines: NSC-34, MN-1 for disease modeling
- HEK293T: Standard expression system
- iPSC-derived neurons: Patient-specific models with TARDBP mutations
- Astrocytes: Glial contribution to pathology
- Brain organoids: Patient-derived, show TDP-43 pathology
- ALS-on-a-chip: Microfluidic models
- Co-cultures: Neuron-glia interactions
| Model |
Approach |
Phenotype |
Notes |
| TDP-43WT |
Wild-type overexpression |
Motor dysfunction |
Dose-dependent |
| TDP-43Q331K |
Human mutant knockin |
Age-dependent ALS |
Most physiological |
| TDP-43M337V |
Mutant overexpression |
Rapid onset |
Robust phenotype |
| TDP-43ΔNLS |
NLS deletion |
Cytoplasmic TDP-43 |
Loss of nuclear function |
| Tg(WT) |
Wild-type expression |
Mild phenotype |
Overexpression effects |
| Tg(G298S) |
Mutant expression |
ALS/FTD phenotype |
Variable |
- Nuclear depletion is sufficient: NLS mutants cause neurodegeneration
- Cell non-autonomous: Glia contribute to motor neuron death
- Propagation: Inoculated brain homogenates transmit pathology
- Mitochondrial defects: Early energy metabolism changes
- Splicing alterations: Dysregulation of critical neuronal transcripts
- Therapeutic testing: Models enable drug screening
- C. elegans: Rapid screening model
- Drosophila: Genetic tractability
- Zebrafish: Motor neuron development
- Non-human primates: Closest to human disease
- Species differences: Mouse models don't fully replicate human disease
- Incomplete pathology: Often lack full spectrum of inclusions
- Variable expression: Transgene insertion effects
- Phenotype variability: Strain background influences
¶ TDP-43 and Cellular Stress
TDP-43 plays a role in oxidative stress response:
- Direct binding: To oxidative stress response genes
- Translation control: Of antioxidant proteins
- Mitochondrial ROS: TDP-43 affects mitochondrial function
- Therapeutic implications: Antioxidant strategies
TDP-43 pathology affects mitochondria:
- Fragmentation: Altered fission/fusion balance
- Transport deficits: Impaired axonal mitochondrial trafficking
- Energy failure: ATP production reduction
- Mitophagy: Impaired clearance of damaged mitochondria
Endoplasmic reticulum stress is a key pathway:
- UPR activation: Unfolded protein response
- CHOP expression: Pro-apoptotic signaling
- Calcium dysregulation: ER calcium release
- Synergy: With other stress pathways
TDP-43 affects protein quality control:
- Ubiquitin-proteasome system: Overload in disease
- Autophagy-lysosomal pathway: Clearance defects
- Molecular chaperones: Hsp90, Hsp70 involvement
- Aggregate sequestration: Of degradation machinery
Astrocytes play a crucial role in TDP-43 pathology:
- Reactive gliosis: GFAP upregulation in disease
- Secreted factors: Inflammatory cytokines
- Neuronal support: Loss of protective functions
- Non-cell autonomous: Astrocyte-to-neuron toxicity
Microglia contribute to disease progression:
- Chronic activation: In ALS/FTD brain
- Phagocytic function: May clear or spread pathology
- TREM2: Variant affects disease progression
- Therapeutic target: Modulation strategies
Oligodendrocytes are also affected:
- White matter changes: Observed in MRI
- Myelin dysfunction: Supporting evidence
- Energy support: Metabolic coupling disruption
TDP-43 can spread between cells:
- Mechanisms: Exosomes, tunneling nanotubes, direct transfer
- Prion-like: Template-driven aggregation
- Neural networks: Anatomical pathways
- Therapeutic challenge: Preventing spread
Extracellular vesicles carry TDP-43:
- Release: From affected neurons
- Uptake: By neighboring cells
- Seed formation: Initiate aggregation
- Detection: In biofluids
Pathological TDP-43 seeds normal protein:
- Conformational conversion: Native to pathological
- Strain variation: Different conformations
- Inheritance: Of aggregation states
- Detection: RT-QuIC, PMCA assays
¶ Clinical Features and Diagnosis
- Muscle weakness: Progressive, focal onset
- Fasciculations: Muscle twitches
- Spasticity: Upper motor neuron signs
- Respiratory failure: Cause of mortality
- Cognitive changes: In ALS/FTD overlap
- Behavioral variant: Personality changes
- Language variants: Primary progressive aphasia
- Motor features: In overlap cases
- Disease progression: Variable rate
- El Escorial revised: Clinical criteria
- Awaji criteria: EMG additions
- Gold Coast: Simplified diagnostic criteria
- Rascovsky criteria: Behavioral variant
- Neary criteria: Language variants
- Biomarker support: Imaging, CSF
- Incidence: 1-2 per 100,000 annually
- Prevalence: 4-6 per 100,000
- Age of onset: Median 55-65 years
- Sex ratio: Male:female 1.5:1
- Sporadic: 90-95% of cases
- Familial: 5-10% of cases
- Incidence: 3-4 per 100,000
- Prevalence: 10-15 per 100,000
- Age of onset: 45-65 years (younger than AD)
- Equal sex distribution: No strong gender bias
- Subtypes: Variable frequencies
¶ Economic and Social Impact
- Healthcare costs: Extremely high per patient
- Informal care: Substantial caregiver burden
- Lost productivity: Both patients and caregivers
- Quality of life: Severe impact on patients and families
- Government: NIH, foundations
- Industry: Pharmaceutical investments
- Patient advocacy: Critical role in awareness
| Trial |
Agent |
Target |
Phase |
| Various |
Antisense oligonucleotides |
TARDBP |
Pre-clinical |
| Multiple |
Small molecule modulators |
Aggregation |
Phase 1/2 |
| Studies |
Cell therapy |
Motor neuron replacement |
Early phase |
| Trials |
Gene therapy |
Various |
Various |
- Biomarker development: Need for patient selection
- Endpoint validation: Clinical outcome measures
- Trial design: Biomarker-driven enrichment
- Combination approaches: Likely needed
TDP-43 represents a central pathological protein in ALS and FTD, with implications for understanding disease mechanisms and developing therapies. The protein's normal functions in RNA metabolism, combined with its pathological aggregation, provide multiple therapeutic targets. Despite significant progress in understanding TDP-43 biology, effective disease-modifying treatments remain an urgent unmet need. Future directions include strain-specific therapies, precision medicine approaches, and combination strategies targeting multiple aspects of TDP-43 pathobiology.